The assistant professor of neurology and codirector of the Neurology Residency Program at MedStar Georgetown University Hospital shared his thoughts on the 2022 ATMRD Congress and the steps forward made in patient awareness of therapeutic options. [WATCH TIME: 3 minutes]
WATCH TIME: 3 minutes
“Botulinum toxins have been around for 30 years, but they’re still new. That’s the amazing thing about it. Every day I see patients who come in and tell me, ‘How long has this been going on for? This is the first time I’m getting injected.’ I hate to tell them this has been around for 30 years, but the awareness of botulinum toxins continues to grow.”
This month, the PMD Alliance and Georgetown University came together to host the first annual Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress in Washington, DC, June 17-19, 2022. The meeting featured hundreds of clinicians focused on the treatment of movement disorders, with sessions covering novel therapeutics and management tactics, and providing lessons in clinical care.
Laxman Bahroo, DO, assistant professor of neurology, and codirector, Neurology Residency Program, MedStar Georgetown University Hospital, gave one such talk on the second day of the meeting, keying in on the utility of botulinum toxins in the treatment of Parkinson disease (PD). Despite these injectable therapies having been around for quite some time, patient and provider awareness about their use is not as widespread as one would expect.
In a conversation with the PMD Alliance at the meeting, Bahroo shared his perspective on what the meeting offered to those in attendance, and how important it is to understand the use of these not-so-novel treatment options. Additionally, he offered his advice on how to transition patients to these botulinum toxins and the variety of uses for these medicines.